1.G3BP: a promising target for cancer therapy.
Acta Pharmaceutica Sinica 2010;45(8):945-51
G3BP (Ras-GTPase-activating protein SH3 domain binding protein), a protein which binds to RasGAP SH3 domain, belongs to RNA-binding protein family, implicating in the downstream of Ras signaling. G3BP harbors the activities of endoribonuclease and DNA helicase, and can induce stress granules formation. G3BP plays a general role in the signal pathways of cell proliferation, differentiation, apoptosis and RNA metabolism. It has been shown to be over-expressed in a number of human malignancies and has a close relationship with tumor invasion and metastasis. Given that it has been implicated in several pathways that are known to be involved in cancer biology, G3BP may provide a new target for cancer therapy.
2.Sphingosine kinase 1 and tumor.
Caixia ZHANG ; Hongwei HE ; Rongguang SHAO
Acta Pharmaceutica Sinica 2013;48(7):971-8
Sphingolipids as an important regulator play a critical role in the cell biological functions. Among them, ceramide (Cer) and sphingosine (Sph) induce apoptosis and inhibit cell proliferation; on the contrary sphingosine 1-phosphate (S1P) promotes cell survival and proliferation. The balance between ceramide/sphingosine and S1P forms a so-called "sphingolipid-rheostat", which decides the cell fate. Sphingosine kinases, which catalyze the phosphorylation of sphingosine to S1P, are critical regulators of this balance. Here, we review the role of sphingosine kinase 1 (SphK1) in regulating fundamental biological processes and tumorigenesis and the potential of SphK1 as a new target for cancer therapeutics.
3.Phosphoprotein EBP50 suppresses proliferation of breast cancer by inhibiting activity of ERK1/2 in MCF-7 cell line
Hong LIU ; Yan MA ; Rongguang SHAO
Chinese Pharmacological Bulletin 2015;(1):55-59
Aim To investigate the relationship be-tween phosphoprotein EBP50 and the proliferation of breast cancer in MCF-7 cells. Methods The quali-fied recombinant plasmid sh-EBP50-pGPU6/Neo was transfected into MCF-7 cells with EBP50 knocking down. The expression of EBP50, c-myc, p-ERK1/2, and ERK1/2 was detected by Western blot. The prolif-eration ability of cells was detected by sulforhodamine B assay. Results The EBP50 knocking down plasmid was constructed successfully. MCF-7 cells with EBP50 knocking down had been established successfully. Knocking down of EBP50 increased the proliferation of MCF-7 significantly, and partially augmented the ex-pression of c-myc and phosphorylation of ERK1/2 . However, knocking down of EBP50 did not impact the expression of ERK1/2 . Conclusion EBP50 suppres-ses the proliferation of breast cancer cell through inhib-iting the activity of ERK1/2 in MCF-7 cell line.
4.Potential targets for anti-liver fibrosis.
Shuangshuang ZHAO ; Rongguang SHAO ; Hongwei HE
Acta Pharmaceutica Sinica 2014;49(10):1365-71
Liver fibrosis is a pathological process of the excessive accumulation of extracellular matrix, especially collagen al (I) in liver. Ultimately, hepatic fibrosis leads to cirrhosis or hepatic failure. Liver fibrosis and early cirrhosis can be reversed, thus control of the development of liver fibrosis is very important for preventive treatment of cirrhosis and hepatic failure. This is a review of potential targets for anti-hepatic fibrosis based on plenty of publications, including TGF-β1 and integrin α(v) and so on, aimed at providing novel therapeutic targets in liver fibrosis.
5.Therapeutics, genomics and epigenomics of retinoblastoma
Wenping SONG ; Rongguang SHAO ; Liang LI
Chinese Journal of Biochemical Pharmaceutics 2016;36(6):1-5
Retinoblastoma is the most common pediatric retinal tumor initiated by biallelic inactivation of the retinoblastoma gene ( RB1 ) , affecting roughly 1 in 15000 children with 1100 new cases each year.In China, RB remains a potentially devastating disease while lack of early diagnosis and aggressive treatment strategies.Moreover, RB patients individually show a variety of drug response to regular systemic chemotherapy since intensive chemotherapy and long-term follow-up are not as readily available.The majority of patients with advanced diseases require enucleation which affects the future quality of children life.Recent studies showed that alterations in genomics and epigenomics of RB play very important roles in RB progress and therapy.We thereby review current understanding changes of genomics and epigenomics in RB as potential prognostic and therapeutic targets.
6.Advances in antibody drug for cancer targeted therapy
Rui CAO ; Rongguang SHAO ; Liang LI
Chinese Journal of Biochemical Pharmaceutics 2016;36(6):15-18
With the recent understanding of cancer biology, physiopathology, and cancer genetics& genomics, new treatments and methodologies are constantly developed, including on the development and application of molecular targeted drugs for cancer therapy have been widespread concerned.Antibody-based drugs targeting over-expressed oncogenes or other functional proteins in cancer with its high specificity, less side-effects and significant clinical efficacy became rapidly the hot-spot of anti-tumor drug research.Currently, there are already more than 20 of anti-tumor antibody-based drugs approved for clinical application, and achieved remarkable results.This article summarizes the development and current situation of monoclonal antibody-based drug research for cancer therapy, as well as their anti-tumor mechanism of action.At the same time summarizes the new advances in cancer research in the field of monoclonal antibody drugs made,and its prospects as well as shortcomings were outlined.
7.Antitumor Activity of the Conjugates Composed of C1027, an Anticancer Antibiotic, and Monoclonal Antibody
Yongsu ZHEN ; Rongguang SHAO ; Min JIANG
Chinese Journal of Cancer Biotherapy 1995;0(02):-
C1027, an anticancer antibiotic, showed extremely potent cytotoxicity against cultured cancer cells, being over 10,000-fold more potent than adriamycin. C1027 acted rapidly; DNA synthesis of hepatoma cells was suppressed within 10 mintus of exposure. C1027 consists of two moieties, a new enediyne chromophore and an apoprotein; the chromophore serves as the active part of the molecule. C1027 molecule can be dissociated and reconstituted. The reconstituted C1027 was as potent as natural C1027. Through a newly developed method, enriched conjugation C1027 was conjugated to monoclonal antibodies. As determined by clonogenic assay, the conjugates displayed highly-potent, specific cytotoxicity to target cancer cells. The conjugates exerted marked therapeutic effects against hepatoma and gastric cancer xenografts in nude mice; at tolerable dose, tumor inhibition rate reached 85% (P
8.Studies of cancer therapeutic pharmacology in China:Data from 2001 applications of NSFC
Yao DAI ; Lei WU ; Rongguang SHAO
Chinese Pharmacological Bulletin 1986;0(05):-
The number of projects from free applications of the national natural science foundation of China (NSFC) about pharmacology of antitumor drugs in 2001 increased evidently than before. Those projects were mainly about the exploration of the natural materials with antitumor activity, investigation in new targets of antitumor drugs, study in the inhibition of angiogenesis in tumor cells,etc. The tumor pharmacology in China has made some progress, but it still lags much behind the international study level. Basic work and creative ideas should be strengthened for further development.
9.An overview of antibody-based cancer therapy.
Qingfang MIAO ; Rongguang SHAO ; Yongsu ZHEN
Acta Pharmaceutica Sinica 2012;47(10):1261-8
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Approximate 17 monoclonal antibodies have been approved as cancer therapeutics since 1997. Antibody-drug conjugates (ADC) are powerful new treatment options for cancer, and naked antibodies have recently achieved remarkable success. The safety and effectiveness of therapeutic mAbs in oncology vary depending on the nature of the target antigen and the mechanisms of tumor cell killing. This review provides a summary of the current state of antibody-based cancer therapy, including the mechanisms of tumor cell killing by antibodies, tumor antigens as antibody targets, clinical effectiveness of antibodies in cancer patients and nanoparticles-based ADCs.
10.The synergistic effect of lidamycin and rituximab on human B cell lymphoma.
Yiran SUN ; Shenghua ZHANG ; Rongguang SHAO ; Hongwei HE
Acta Pharmaceutica Sinica 2014;49(2):198-203
This study aimed to investigate the synergistic effect of lidamycin (LDM) and rituximab on human B cell lymphoma Ramos cells. Cell proliferation was measured using MTS assay, cell apoptosis was analyzed by Annexin V-FITC/PI assay, the expression of apoptosis related proteins was analyzed by Western blotting, and the in vivo lymphoma inhibition was verified using BALB/c mice inoculated via tail vein using Ramos cells which stably expressed pEGFP-N1 plasmid. The results showed that, after the pretreatment with rituximab for 48 h, rituximab and LDM showed significantly synergistic effects on cell proliferation. Cells in combined treatment group had a higher apoptosis rate than that in LDM treatment group. Compared with the LDM treatment group, the expression of apoptosis-related proteins such as Cleaved caspase-3, Cleaved caspase-7, Cleaved caspase-9 and Cleaved PARP in combined treatment groups increased, and expression of cIAP-2 and Bcl-2 decreased. The result of in vivo experiment showed that, in the combined treatment group, the survival time of BALB/c mice was significantly longer than the mice in control group and LDM treatment group, and the degree of tumor accumulation and metastasis to lymph nodes and spleen was lower.